JNJ-89862175 treatment for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1, open-label, multi-center study uses a two-part design: Part 1 is a dose-escalation to identify recommended Phase 2 dose(s) (RP2Ds) and Part 2 expands cohorts at the RP2Ds to further characterize safety and preliminary activity. Participants will receive JNJ-89862175 with scheduled safety monitoring, laboratory tests, and imaging to track adverse events and tumor response. Eligible patients have metastatic or unresectable lung adenocarcinoma, clear cell or papillary renal cell carcinoma, endometrioid ovarian cancer, or endometrioid uterine carcinoma and an ECOG performance status of 0–1. Key exclusions include active uncontrolled CNS disease, recent clinically significant cardiovascular events, prior solid organ or hematologic stem cell transplant, and known hypersensitivity to the drug's excipients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must have histologically or cytologically confirmed, metastatic or unresectable solid tumor of lung adenocarcinoma, renal cell carcinoma (RCC): clear cell or papillary carcinoma, endometrioid ovarian cancer and endometrioid uterine carcinoma
* Have an eastern cooperative oncology group (ECOG) performance status of 0 to 1 at screening
* Participants on study drug and for 4 months after the last dose of study drug must not breastfeed or be pregnant, not donate gametes (that is, eggs or sperms) or freeze for future use for the purposes of assisted reproduction and wear an external condom

Exclusion Criteria:

* Active central nervous system (CNS) involvement unless clinically stable
* History of clinically significant cardiovascular disease within 6 months prior to signing informed consent
* History of solid organ or hematologic stem cell transplantation
* Known allergies, hypersensitivity, or intolerance to excipients of JNJ-89862175
* Has prior or concurrent second malignancy (other than the disease under study) in which the natural history or treatment is likely to interfere with safety endpoints or efficacy of the study drug

Where it's running

• AdventHealth Orlando
  Orlando, Florida, United States Recruiting
• Massachusetts General Hospital Cancer Center
  Boston, Massachusetts, United States Recruiting
• NEXT Oncology
  Irving, Texas, United States Recruiting
• Centre Leon Berard
  Lyon, France Recruiting
• Gustave Roussy
  Villejuif, France Recruiting
• Severance Hospital Yonsei University Health System
  Seoul, South Korea Recruiting

Study contacts

• Study coordinator: Study Contact
• Email: Participate-In-This-Study1@its.jnj.com
• Phone: 844-434-4210

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• JNJ-95437446 for advanced-stage solid tumors

  This tests JNJ-95437446 to find a safe dose and check tolerability in people with advanced solid tumors, including colorectal cancer.

  Recruiting at 10 sites Phase 1 Janssen Research & Development, LLC · Sarasota, Florida and 9 other locations · NCT07107230

• JNJ-101556143 plus Best Supportive Care for metastatic prostate cancer

  This study tests whether adding JNJ-101556143 to standard supportive care helps people with metastatic, hormone-resistant prostate cancer live longer than those who receive placebo plus supportive care.

  Recruiting at 4 sites Phase 3 Janssen Research & Development, LLC · El Paso, Texas and 3 other locations · NCT07906717

• Testing JNJ-101556143 in men with advanced prostate cancer that no longer responds to hormone therapy

  This study tests JNJ-101556143 in men with metastatic, hormone-resistant prostate cancer to see if tumors shrink or disappear.

  Recruiting at 14 sites Phase 2 Janssen Research & Development, LLC · Largo, Florida and 13 other locations · NCT07832292

• Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease

  This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen Research & Development, LLC · Amiens · NCT07822529

• New treatment option for advanced prostate cancer using JNJ-98768111

  A first-in-human study tests JNJ-98768111 to see how safe it is and find the best dose for people with advanced prostate cancer who have already tried other therapies.

  Recruiting at 6 sites Phase 1 Janssen Research & Development, LLC · Sarasota, Florida and 5 other locations · NCT07746713

• Test of JNJ-95597528 vs placebo in adults with moderate to severe asthma

  This trial checks whether JNJ-95597528 helps adults with moderate to severe asthma when added to their current treatment, compared with a placebo.

  Recruiting at 19 sites Phase 2 Janssen Research & Development, LLC · Westminster, California and 18 other locations · NCT07746687

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.